Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions 51% of the business is held by the top 10 shareholders Insider...